|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 20 amino acid peptide near the center of the human Spred1.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||2.5 µg/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 1 publications below|
A suggested positive control is mouse brain tissue lysate.
PA5-20617 can be used with blocking peptide PEP-0737.
The Ras-MAP kinase pathway is essential for the differentiation of neuronal cells and myocytes; it is inhibited by Spred1, a member of the Sprouty family of proteins. Spred1 acts by suppressing the phosphorylation and activation of Raf. The Spred proteins have also been implicated in the negative feedback regulation of FGF signaling in embryogenesis and angiogenesis. Further studies have shown that expression levels of Spred1 and Spred2 proteins are inversely correlated with the incidence of tumor invasion and metastasis in human hepatocellular carcinoma (HHC), suggesting that these proteins could be useful as prognostic factors and therapeutic targets in HCC. Defects in this gene are a cause of neurofibromatosis type 1-like syndrome (NFLS). This Spred1 antibody is predicted to have no cross-reactivity to Spred2 or Spred3.
IP-MS enrichment of SPRED1 (LFQ intensity): SPRED1 was enriched 658-fold from SKMEL5 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and SPRED1 antibody (Part No. PA5-20617). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.
PA5-20617 was used in western blot to investigate the contribution of miR-31 to lung tumorigenesis
|Edmonds MD,Boyd KL,Moyo T,Mitra R,Duszynski R,Arrate MP,Chen X,Zhao Z,Blackwell TS,Andl T,Eischen CM||The Journal of clinical investigation (126:349)||2016|